Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > NanoViricides, Inc. Participated In WHO Meeting On Dengue Therapeutics

Abstract:
Company to File Annual Report Shortly

NanoViricides, Inc. Participated In WHO Meeting On Dengue Therapeutics

WEST HAVEN, CT | Posted on October 20th, 2008

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), said that it participated in a meeting of international experts on Dengue Therapeutics held by the Special Programme for Research and Training in Tropical Diseases (TDR), of the World Health Organization (WHO), in Geneva, Switzerland on October 2, 2008.

"Viral load reduction was clearly recognized as an important goal in Dengue treatment at this meeting. Nanoviricides are well suited for Dengue treatment because they are specifically designed for viral load reduction. We believe that our novel nanomedicine-based direct antiviral approach will be of great value in combating the Dengue viruses," said Anil R. Diwan, PhD, President of the Company, who participated in the meeting.

In another note, the Company clarified that the deadline for filing its Annual Report on Form 10-K, within the thirty day grace period allowed, is October 29, 2008. The Company, its counsel, public auditors and internal accountants, are committed to finalizing and filing the report accordingly. The Company expects to file the Annual Report shortly. When the Company files its annual report, the "E" will be removed from the Company's symbol, changing it back to the normal NNVC. The presence of an "e" (i.e. NNVCE) does not constitute a trading halt or delisting of the company's stock. It resulted from the original filing date for the annual report being exceeded.

NIAID experts see dengue as an important potential threat to the US public health (http://www.nih.gov/news/pr/jan2008/niaid-08.htm). The mosquito vectors that carry dengue viruses have been found in 36 or more states. Human infections in southern states have also been reported. Worldwide, dengue is among the most important reemerging infectious diseases with an estimated 50 to 100 million annual cases and 22,000 deaths. Dengue has become endemic in many tropical countries. (www.iht.com/articles/2008/05/15/healthscience/13brod.php).

Dengue fever is caused by one of four dengue virus types. Most people when they get the first infection have mild disease. A second infection with a different type of dengue virus can lead to a severe and life-threatening form of dengue disease, called severe dengue or dengue hemorrhagic fever. Thus people who have had a primary infection are primed for a severe form of the disease. Dengue severity is expected to continue to increase worldwide.

There are currently no drug treatments or vaccines against dengue.

####

About NanoViricides, Inc.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, EKC, hepatitis C, rabies, dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements of the company to be different from those expressed or implied including the success of the Company's research and development efforts, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process, described in the “Management’s Discussion and Analysis” section of the Company’s Form 10-KSB and other reports and filings with the Securities and Exchange Commission.

For more information, please click here

Contacts:
NanoViricides, Inc.
Amanda Schuon
310-550-7200

Copyright © Business Wire 2008

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

East China University of Science and Technology Purchases Nanonex Advanced Nanoimprint Tool NX-B200 July 30th, 2014

Watching Schrödinger's cat die (or come to life): Steering quantum evolution & using probes to conduct continuous error correction in quantum computers July 30th, 2014

From Narrow to Broad July 30th, 2014

FLAG-ERA and TNT2014 join efforts: Graphene Networking at its higher level in Barcelona: Encourage the participation in a joint transnational call July 30th, 2014

Nanomedicine

New imaging agent provides better picture of the gut July 30th, 2014

Zenosense, Inc. July 29th, 2014

Optimum inertial design for self-propulsion: A new study investigates the effects of small but finite inertia on the propulsion of micro and nano-scale swimming machines July 29th, 2014

FEI adds Phase Plate Technology and Titan Halo TEM to its Structural Biology Product Portfolio: New solutions provide the high-quality imaging and contrast necessary to analyze the 3D structure of molecules and molecular complexes July 28th, 2014

Announcements

University of Manchester selects Anasys AFM-IR for coatings and corrosion research July 30th, 2014

Nature inspires a greener way to make colorful plastics July 30th, 2014

Analytical solutions from Malvern Instruments support University of Wisconsin-Milwaukee researchers in understanding environmental effects of nanomaterials July 30th, 2014

FEI Unveils New Solutions for Faster Time-to-Analysis in Metals Research July 30th, 2014

Interviews/Book Reviews/Essays/Reports/Podcasts/Journals

Watching Schrödinger's cat die (or come to life): Steering quantum evolution & using probes to conduct continuous error correction in quantum computers July 30th, 2014

From Narrow to Broad July 30th, 2014

Nature inspires a greener way to make colorful plastics July 30th, 2014

A new way to make microstructured surfaces: Method can produce strong, lightweight materials with specific surface properties July 29th, 2014

Events/Classes

FLAG-ERA and TNT2014 join efforts: Graphene Networking at its higher level in Barcelona: Encourage the participation in a joint transnational call July 30th, 2014

FEI Unveils New Solutions for Faster Time-to-Analysis in Metals Research July 30th, 2014

WITec to host the 11th Confocal Raman Imaging Symposium from September 29th - October 1st in Ulm, Germany July 28th, 2014

FEI adds Phase Plate Technology and Titan Halo TEM to its Structural Biology Product Portfolio: New solutions provide the high-quality imaging and contrast necessary to analyze the 3D structure of molecules and molecular complexes July 28th, 2014

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE